Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. Editorial Article uri icon

Overview

publication date

  • November 1, 2017

Research

keywords

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Cost-Benefit Analysis
  • Lung Neoplasms

Identity

Scopus Document Identifier

  • 85051742202

Digital Object Identifier (DOI)

  • 10.1093/jnci/djx125

PubMed ID

  • 29059436

Additional Document Info

volume

  • 109

issue

  • 11